Q4 Earnings Forecast for CADL Issued By HC Wainwright

Candel Therapeutics, Inc. (NASDAQ:CADL) – Investment analysts at HC Wainwright issued their Q4 2024 earnings per share estimates for Candel Therapeutics in a research note issued on Monday, November 18th. HC Wainwright analyst V. Bernardino expects that the company will earn ($0.30) per share for the quarter. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Candel Therapeutics’ current full-year earnings is ($0.91) per share.

Candel Therapeutics Price Performance

Shares of NASDAQ:CADL opened at $3.98 on Tuesday. Candel Therapeutics has a 1-year low of $0.77 and a 1-year high of $14.30. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.18 and a quick ratio of 1.18. The business has a fifty day moving average price of $5.90 and a 200-day moving average price of $6.67. The company has a market capitalization of $129.25 million, a PE ratio of -2.30 and a beta of -0.88.

Institutional Investors Weigh In On Candel Therapeutics

Institutional investors have recently modified their holdings of the business. State Street Corp boosted its position in Candel Therapeutics by 4.1% in the third quarter. State Street Corp now owns 492,005 shares of the company’s stock worth $3,410,000 after purchasing an additional 19,207 shares during the last quarter. Geode Capital Management LLC boosted its position in Candel Therapeutics by 12.8% in the third quarter. Geode Capital Management LLC now owns 448,997 shares of the company’s stock worth $3,112,000 after purchasing an additional 51,111 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in shares of Candel Therapeutics during the 2nd quarter valued at about $338,000. Barclays PLC lifted its position in shares of Candel Therapeutics by 327.1% during the 3rd quarter. Barclays PLC now owns 28,688 shares of the company’s stock valued at $199,000 after buying an additional 21,971 shares in the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Candel Therapeutics during the 2nd quarter valued at about $162,000. 13.93% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Candel Therapeutics

In related news, major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of the stock in a transaction on Monday, October 14th. The stock was sold at an average price of $6.02, for a total transaction of $90,300.00. Following the sale, the insider now directly owns 929,873 shares of the company’s stock, valued at $5,597,835.46. This trade represents a 1.59 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold 31,800 shares of company stock valued at $193,380 over the last ninety days. Insiders own 41.60% of the company’s stock.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.